The University of Southampton
University of Southampton Institutional Repository

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

BACKGROUND: Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than 18 years compared with the same data that are available in adults.

METHODS: COV006 is a phase 2, single-blind, randomised, controlled trial of ChAdOx1 nCoV-19 (AZD1222) in children and adolescents at four trial sites in the UK. Healthy participants aged 6-17 years, who did not have a history of chronic respiratory conditions, laboratory-confirmed COVID-19, or previously received capsular group B meningococcal vaccine (the control), were randomly assigned to four groups (4:1:4:1) to receive two intramuscular doses of 5 × 1010 viral particles of ChAdOx1 nCoV-19 or control, 28 days or 84 days apart. Participants, clinical investigators, and the laboratory team were masked to treatment allocation. Study groups were stratified by age, and participants aged 12-17 years were enrolled before those aged 6-11 years. Due to the restrictions in the use of ChAdOx1 nCoV-19 in people younger than 30 years that were introduced during the study, only participants aged 12-17 years who were randomly assigned to the 28-day interval group had received their vaccinations at the intended interval (day 28). The remaining participants received their second dose at day 112. The primary outcome was assessment of safety and tolerability in the safety population, which included all participants who received at least one dose of the study drug. The secondary outcome was immunogenicity, which was assessed in participants who were seronegative to the nucleocapsid protein at baseline and received both prime and boost vaccine. This study is registered with ISRCTN (15638344).

FINDINGS: Between Feb 15 and April 2, 2021, 262 participants (150 [57%] participants aged 12-17 years and 112 [43%] aged 6-11 years; due to the change in the UK vaccination policy, the study terminated recruitment of the younger age group before the planned number of participants had been enrolled) were randomly assigned to receive vaccination with two doses of either ChAdOx1 nCoV-19 (n=211 [n=105 at day 28 and n=106 at day 84]) or control (n=51 [n=26 at day 28 and n=25 at day 84]). One participant in the ChAdOx1 nCoV-19 day 28 group in the younger age bracket withdrew their consent before receiving a first dose. Of the participants who received ChAdOx1 nCoV-19, 169 (80%) of 210 participants reported at least one solicited local or systemic adverse event up to 7 days following the first dose, and 146 (76%) of 193 participants following the second dose. No serious adverse events related to ChAdOx1 nCoV-19 administration were recorded by the data cutoff date on Oct 28, 2021. Of the participants who received at least one dose of ChAdOx1 nCoV-19, there were 128 unsolicited adverse events up to 28 days after vaccination reported by 83 (40%) of 210 participants. One participant aged 6-11 years receiving ChAdOx1 nCoV-19 reported a grade 4 fever of 40·2°C on day 1 following first vaccination, which resolved within 24 h. Pain and tenderness were the most common local solicited adverse events for all the ChAdOx1 nCoV-19 and capsular group B meningococcal groups following both doses. Of the 242 participants with available serostatus data, 14 (6%) were seropositive at baseline. Serostatus data were not available for 20 (8%) of 262 participants. Among seronegative participants who received ChAdOx1 nCoV-19, anti-SARS-CoV-2 IgG and pseudoneutralising antibody titres at day 28 after the second dose were higher in participants aged 12-17 years with a longer interval between doses (geometric means of 73 371 arbitrary units [AU]/mL [95% CI 58 685-91 733] and 299 half-maximal inhibitory concentration [IC50; 95% CI 230-390]) compared with those aged 12-17 years who received their vaccines 28 days apart (43 280 AU/mL [95% CI 35 852-52 246] and 150 IC50 [95% CI 116-194]). Humoral responses were higher in those aged 6-11 years than in those aged 12-17 years receiving their second dose at the same 112-day interval (geometric mean ratios 1·48 [95% CI 1·07-2·07] for anti-SARS-CoV-2 IgG and 2·96 [1·89-4·62] for pseudoneutralising antibody titres). Cellular responses peaked after a first dose of ChAdOx1 nCoV-19 across all age and interval groups and remained above baseline after a second vaccination.

INTERPRETATION: ChAdOx1 nCoV-19 is well tolerated and immunogenic in children aged 6-17 years, inducing concentrations of antibody that are similar to those associated with high efficacy in phase 3 studies in adults. No safety concerns were raised in this trial.

FUNDING: AstraZeneca and the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.

Adolescent, Adult, Antibodies, Viral, COVID-19 Vaccines/adverse effects, COVID-19/prevention & control, ChAdOx1 nCoV-19, Child, Double-Blind Method, Humans, Immunoglobulin G, Meningococcal Vaccines, SARS-CoV-2, Single-Blind Method
0140-6736
2212-2225
Li, Grace
11c858e9-8616-4580-b271-cdd5fabbb167
Cappuccini, Federica
0622e2a3-3cd8-4398-99ea-8b09d59366f1
Marchevsky, Natalie G
0a405c24-3856-4663-8674-cd63dd9d9971
Aley, Parvinder K
47682c89-e7f3-481a-9176-23bb4053ba36
Aley, Robert
37b4e4d8-c6dc-4282-9be6-97d353f382b9
Anslow, Rachel
ecef4058-6396-4989-bd95-902439d2e1ff
Bibi, Sagida
bd84c45a-68e3-47a1-b5ea-20b41042e9bf
Cathie, Katrina
4b772af2-4b34-45d4-866a-fb934376e1cd
Clutterbuck, Elizabeth
db4945e9-ca8e-44f8-8030-4c0160956e71
Faust, Saul N
f97df780-9f9b-418e-b349-7adf63e150c1
Feng, Shuo
7bed8cb4-d66f-4ef1-b3fb-f9cc0c996be4
Heath, Paul T
b9b6e0e4-6bd0-4c16-b9f6-607b00137fe4
Kerridge, Simon
81f15fce-1c9e-4338-b5e0-cbaf546a83e9
Lelliott, Alice
a06d226a-0370-48ed-beda-6bf6672520fa
Mujadidi, Yama
bffb5a37-2ab0-4883-9001-c00b4e996c8c
Ng, Khuen Foong
fb7a2f33-cadc-4291-bb30-c5546fa82419
Rhead, Sarah
9fd57d02-10cd-445d-8550-2c6beac33e2b
Roberts, Hannah
1f54c607-ade3-44a5-96ae-f58647d2c3c9
Robinson, Hannah
5db3b2f0-c4a0-4cf3-a0e7-11a85972e000
Roderick, Marion R
fa046362-8f5d-42e2-8f86-89beb557487f
Singh, Nisha
cf2bc6b0-8d3d-44c8-98e6-05005334112a
Smith, David
cc9b7ecf-1b3e-4670-9127-21087dc2e26a
Snape, Matthew D
ea21c8b9-e907-4914-9052-ae9eb56f54d7
Song, Rinn
720506ab-3458-4ba9-9494-be5b46030119
Tang, Karly
696523ef-a137-45d9-82a8-1581d5da4d02
Yao, Andy
a33fc84c-7f2c-4cc5-98df-2cc6f1923af9
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Lambe, Teresa
d5fd6770-9ef0-45a9-a23a-9a7d865009a6
Pollard, Andrew J
f54083f3-c730-4ecb-937e-6fb11fdd6a21
et al.
COV006 study team
Li, Grace
11c858e9-8616-4580-b271-cdd5fabbb167
Cappuccini, Federica
0622e2a3-3cd8-4398-99ea-8b09d59366f1
Marchevsky, Natalie G
0a405c24-3856-4663-8674-cd63dd9d9971
Aley, Parvinder K
47682c89-e7f3-481a-9176-23bb4053ba36
Aley, Robert
37b4e4d8-c6dc-4282-9be6-97d353f382b9
Anslow, Rachel
ecef4058-6396-4989-bd95-902439d2e1ff
Bibi, Sagida
bd84c45a-68e3-47a1-b5ea-20b41042e9bf
Cathie, Katrina
4b772af2-4b34-45d4-866a-fb934376e1cd
Clutterbuck, Elizabeth
db4945e9-ca8e-44f8-8030-4c0160956e71
Faust, Saul N
f97df780-9f9b-418e-b349-7adf63e150c1
Feng, Shuo
7bed8cb4-d66f-4ef1-b3fb-f9cc0c996be4
Heath, Paul T
b9b6e0e4-6bd0-4c16-b9f6-607b00137fe4
Kerridge, Simon
81f15fce-1c9e-4338-b5e0-cbaf546a83e9
Lelliott, Alice
a06d226a-0370-48ed-beda-6bf6672520fa
Mujadidi, Yama
bffb5a37-2ab0-4883-9001-c00b4e996c8c
Ng, Khuen Foong
fb7a2f33-cadc-4291-bb30-c5546fa82419
Rhead, Sarah
9fd57d02-10cd-445d-8550-2c6beac33e2b
Roberts, Hannah
1f54c607-ade3-44a5-96ae-f58647d2c3c9
Robinson, Hannah
5db3b2f0-c4a0-4cf3-a0e7-11a85972e000
Roderick, Marion R
fa046362-8f5d-42e2-8f86-89beb557487f
Singh, Nisha
cf2bc6b0-8d3d-44c8-98e6-05005334112a
Smith, David
cc9b7ecf-1b3e-4670-9127-21087dc2e26a
Snape, Matthew D
ea21c8b9-e907-4914-9052-ae9eb56f54d7
Song, Rinn
720506ab-3458-4ba9-9494-be5b46030119
Tang, Karly
696523ef-a137-45d9-82a8-1581d5da4d02
Yao, Andy
a33fc84c-7f2c-4cc5-98df-2cc6f1923af9
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Lambe, Teresa
d5fd6770-9ef0-45a9-a23a-9a7d865009a6
Pollard, Andrew J
f54083f3-c730-4ecb-937e-6fb11fdd6a21

Li, Grace, Cappuccini, Federica, Marchevsky, Natalie G, Aley, Parvinder K, Aley, Robert, Anslow, Rachel, Liu, Xinxue, Lambe, Teresa and Pollard, Andrew J , et al. and COV006 study team (2022) Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. The Lancet, 399 (10342), 2212-2225. (doi:10.1016/S0140-6736(22)00770-X).

Record type: Article

Abstract

BACKGROUND: Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than 18 years compared with the same data that are available in adults.

METHODS: COV006 is a phase 2, single-blind, randomised, controlled trial of ChAdOx1 nCoV-19 (AZD1222) in children and adolescents at four trial sites in the UK. Healthy participants aged 6-17 years, who did not have a history of chronic respiratory conditions, laboratory-confirmed COVID-19, or previously received capsular group B meningococcal vaccine (the control), were randomly assigned to four groups (4:1:4:1) to receive two intramuscular doses of 5 × 1010 viral particles of ChAdOx1 nCoV-19 or control, 28 days or 84 days apart. Participants, clinical investigators, and the laboratory team were masked to treatment allocation. Study groups were stratified by age, and participants aged 12-17 years were enrolled before those aged 6-11 years. Due to the restrictions in the use of ChAdOx1 nCoV-19 in people younger than 30 years that were introduced during the study, only participants aged 12-17 years who were randomly assigned to the 28-day interval group had received their vaccinations at the intended interval (day 28). The remaining participants received their second dose at day 112. The primary outcome was assessment of safety and tolerability in the safety population, which included all participants who received at least one dose of the study drug. The secondary outcome was immunogenicity, which was assessed in participants who were seronegative to the nucleocapsid protein at baseline and received both prime and boost vaccine. This study is registered with ISRCTN (15638344).

FINDINGS: Between Feb 15 and April 2, 2021, 262 participants (150 [57%] participants aged 12-17 years and 112 [43%] aged 6-11 years; due to the change in the UK vaccination policy, the study terminated recruitment of the younger age group before the planned number of participants had been enrolled) were randomly assigned to receive vaccination with two doses of either ChAdOx1 nCoV-19 (n=211 [n=105 at day 28 and n=106 at day 84]) or control (n=51 [n=26 at day 28 and n=25 at day 84]). One participant in the ChAdOx1 nCoV-19 day 28 group in the younger age bracket withdrew their consent before receiving a first dose. Of the participants who received ChAdOx1 nCoV-19, 169 (80%) of 210 participants reported at least one solicited local or systemic adverse event up to 7 days following the first dose, and 146 (76%) of 193 participants following the second dose. No serious adverse events related to ChAdOx1 nCoV-19 administration were recorded by the data cutoff date on Oct 28, 2021. Of the participants who received at least one dose of ChAdOx1 nCoV-19, there were 128 unsolicited adverse events up to 28 days after vaccination reported by 83 (40%) of 210 participants. One participant aged 6-11 years receiving ChAdOx1 nCoV-19 reported a grade 4 fever of 40·2°C on day 1 following first vaccination, which resolved within 24 h. Pain and tenderness were the most common local solicited adverse events for all the ChAdOx1 nCoV-19 and capsular group B meningococcal groups following both doses. Of the 242 participants with available serostatus data, 14 (6%) were seropositive at baseline. Serostatus data were not available for 20 (8%) of 262 participants. Among seronegative participants who received ChAdOx1 nCoV-19, anti-SARS-CoV-2 IgG and pseudoneutralising antibody titres at day 28 after the second dose were higher in participants aged 12-17 years with a longer interval between doses (geometric means of 73 371 arbitrary units [AU]/mL [95% CI 58 685-91 733] and 299 half-maximal inhibitory concentration [IC50; 95% CI 230-390]) compared with those aged 12-17 years who received their vaccines 28 days apart (43 280 AU/mL [95% CI 35 852-52 246] and 150 IC50 [95% CI 116-194]). Humoral responses were higher in those aged 6-11 years than in those aged 12-17 years receiving their second dose at the same 112-day interval (geometric mean ratios 1·48 [95% CI 1·07-2·07] for anti-SARS-CoV-2 IgG and 2·96 [1·89-4·62] for pseudoneutralising antibody titres). Cellular responses peaked after a first dose of ChAdOx1 nCoV-19 across all age and interval groups and remained above baseline after a second vaccination.

INTERPRETATION: ChAdOx1 nCoV-19 is well tolerated and immunogenic in children aged 6-17 years, inducing concentrations of antibody that are similar to those associated with high efficacy in phase 3 studies in adults. No safety concerns were raised in this trial.

FUNDING: AstraZeneca and the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.

Text
1-s2.0-S014067362200770X-main - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

e-pub ahead of print date: 9 June 2022
Published date: 9 June 2022
Additional Information: Funding AstraZeneca and the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.
Keywords: Adolescent, Adult, Antibodies, Viral, COVID-19 Vaccines/adverse effects, COVID-19/prevention & control, ChAdOx1 nCoV-19, Child, Double-Blind Method, Humans, Immunoglobulin G, Meningococcal Vaccines, SARS-CoV-2, Single-Blind Method

Identifiers

Local EPrints ID: 467642
URI: http://eprints.soton.ac.uk/id/eprint/467642
ISSN: 0140-6736
PURE UUID: d5422ff0-dd07-4624-9b2f-c286f5c8fe04
ORCID for Saul N Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 18 Jul 2022 17:43
Last modified: 17 Mar 2024 03:06

Export record

Altmetrics

Contributors

Author: Grace Li
Author: Federica Cappuccini
Author: Natalie G Marchevsky
Author: Parvinder K Aley
Author: Robert Aley
Author: Rachel Anslow
Author: Sagida Bibi
Author: Katrina Cathie
Author: Elizabeth Clutterbuck
Author: Saul N Faust ORCID iD
Author: Shuo Feng
Author: Paul T Heath
Author: Simon Kerridge
Author: Alice Lelliott
Author: Yama Mujadidi
Author: Khuen Foong Ng
Author: Sarah Rhead
Author: Hannah Roberts
Author: Hannah Robinson
Author: Marion R Roderick
Author: Nisha Singh
Author: David Smith
Author: Matthew D Snape
Author: Rinn Song
Author: Karly Tang
Author: Andy Yao
Author: Xinxue Liu
Author: Teresa Lambe
Author: Andrew J Pollard
Corporate Author: et al.
Corporate Author: COV006 study team

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×